Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368 [PMID: 30344420 DOI: 10.3748/wjg.v24.i38.4356]
Corresponding Author of This Article
Wolfgang Kreisel, MD, Emeritus Professor, Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, Freiburg 79106, Germany. wolfgang.kreisel@uniklinik-freiburg.de
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 5 Median ± interquartile range of the absolute values of body weight, portal venous pressure, mean arterial pressure, and heart rate at different time points
CON
FIB
CIR
NaCl (n = 19)
Sil 0.1 mg/kg (n = 18)
Sil 1.0 mg/kg (n = 18)
NaCl (n = 7)
Sil 0.1 mg/kg (n = 15)
Sil 1.0 mg/kg (n = 7)
NaCl (n = 7)
Sil 0.1 mg/kg (n = 7)
Sil 1.0 mg/kg (n = 10)
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Median ± IQR
Body weight (g)
375 ± 15
370 ± 28
380 ± 27
359 ± 35
363 ± 28
361 ± 24
336 ± 40
350 ± 46
337 ± 15
PVP_0 (mmHG)
6.4 ± 0.7
6.6 ± 0.4
6.3 ± 0.7
6.0 ± 0.9
6.2 ± 1.3
6.2 ± 0.9
6.8 ± 1.6
7.5 ± 1.7
7.7 ± 1.1
PVP_10 (mmHG)
6.0 ± 0.9
6.6 ± 0.6
6.6 ± 0.9
5.7 ± 1.2
5.5 ± 1.3
5.1 ± 1.4
6.8 ± 1.4
7.1 ± 1.6
7.1 ± 2.2
PVP_30 (mmHG)
5.9 ± 0.7
6.3 ± 0.7
6.4 ± 0.8
5.3 ± 1.4
5.4 ± 1.3
4.8 ± 1.4
6.5 ± 1.2
6.6 ± 1.0
6.3 ± 1.3
PVP_60 (mmHG)
5.9 ± 0.7
6.3 ± 0.8
6.4 ± 1.1
5.1 ± 1.2
5.2 ± 1.2
4.8 ± 1.5
6.6 ± 2.0
6.3 ± 1.0
5.8 ± 1.2
MAP_0 (mmHG)
89 ± 12
106 ± 14
101 ± 28
65 ± 30
59 ± 21
58 ± 28
49 ± 19
47 ± 15
60 ± 19
MAP_10 (mmHG)
83 ± 20
94 ± 14
85 ± 27
55 ± 25
45 ± 10
42 ± 8
42 ± 11
41 ± 5
38 ± 16
MAP_30 (mmHG)
79 ± 21
88 ± 17
77 ± 21
50 ± 14
43 ± 12
37 ± 6
41 ± 12
35 ± 8
36 ± 8
MAP_60 (mmHG)
76 ± 21
82 ± 23
74 ± 28
44 ± 11
40 ± 8
37 ± 7
38 ± 3
34 ± 5
34 ± 7
HR_0 (bpm)
373 ± 40
377 ± 47
368 ± 31
320 ± 30
335 ± 30
314 ± 22
307 ± 38
308 ± 76
365 ± 28
HR_10 (bpm)
362 ± 55
383 ± 44
380 ± 50
313 ± 23
339 ± 41
351 ± 29
286 ± 33
316 ± 71
374 ± 22
HR_30 (bpm)
356 ± 57
366 ± 52
373 ± 41
291 ± 20
310 ± 43
310 ± 21
268 ± 40
313 ± 57
350 ± 36
HR_60 (bpm)
347 ± 39
359 ± 43
362 ± 49
284 ± 26
304 ± 41
295 ± 33
254 ± 36
302 ± 47
324 ± 30
Table 6 Relative median of differences (%) ± interquartile range of the parameters portal venous pressure, mean arterial pressure, and heart rate
Citation: Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368